Fianlimab
Fianlimab (REGN3767) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells and has anti-tumour activity[1].
Product Specifications
CAS Number
2126132-98-5
Product Name Alternative
REGN3767
UNSPSC
12352203
Target
LAG-3
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/fianlimab.html
Purity
99.04
Solubility
10 mM in DMSO
Smiles
[Fianlimab]
Molecular Weight
(146.46 kDa)
References & Citations
[1]Omid Hamid, et al. Clinical activity of fianlimab (REGN3767), a human anti-LAG-3 monoclonal antibody, combined with cemiplimab (anti-PD-1) in patients (pts) with advanced melanoma.Meeting Abstract | 2021 ASCO Annual Meeting I.|[2]Burova E, et al., Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3-Knockin Mice. Mol Cancer Ther. 2019 Nov;18 (11) :2051-2062.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
bs-8538R-APC-Cy5.5 100 µL
EP4 Polyclonal Antibody, APC-Cy5.5 Conjugated
Sign In for Pricing
View Details 
K2311806 1.0 µg DNA
SUGT1P sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1)
Sign In for Pricing
View Details 